Copyright
©The Author(s) 2015.
World J Gastrointest Pharmacol Ther. Nov 6, 2015; 6(4): 96-104
Published online Nov 6, 2015. doi: 10.4292/wjgpt.v6.i4.96
Published online Nov 6, 2015. doi: 10.4292/wjgpt.v6.i4.96
Table 1 Criteria for functional gastrointestinal disorders related to pain in children
| Functional dyspepsia1 |
| Must include all of the following |
| Persistent or recurrent pain or discomfort centered in the upper abdomen |
| Pain or discomfort not relieved by defecation or associated with onset of a change in stool frequency or form |
| Irritable bowel syndrome1 |
| Must include all of the following |
| Abdominal pain or discomfort associated with 2 or more of the following at least 25% of the time |
| Improved by defecation |
| Onset associated with a change in stool frequency |
| Onset associated with a change in stool form |
| Abdominal migraine |
| Must include all of the following |
| Paroxysmal episodes of intense, acute periumbilical pain lasting at least one hour |
| Intervening periods of usual health lasting at least weeks |
| Pain interferes with normal activity |
| The pain is associated with at least two of the following |
| Anorexia |
| Nausea |
| Vomiting |
| Headache |
| Photophobia |
| Pallor |
| Criteria must be fulfilled at least two times in the preceeding 12 mo |
| Childhood functional abdominal pain1 |
| Must include all of the following |
| Episodic or continuous abdominal pain |
| Does not meet criteria for another FGID |
| Childhood functional abdominal pain syndrome |
| Must include childhood FAP and at least 25% of the time with at least one of the following |
| Some loss of daily function |
| Additional somatic complaints such as headache, limb pain, or difficulty sleeping |
Table 2 Chronological list of placebo controlled drug trials for functional gastrointestinal disorders related to abdominal pain in children and adolescents, including summary of treatment, sample size, and outcome
| Ref. | Treatment | Diagnosis | Sample size (enrolled/completed) | Superior to placebo for pain relief |
| Symon and Russell[44] (1995) | Pitotifen | Abdominal migraine | 16/14 | Yes |
| Kline et al[45] (2001) | Enteric coated peppermint oil capsules | Irritable bowel syndrome | 50/42 | Yes |
| See et al[46] (2001) | Famotidine | Abdominal pain and dyspepsia | 25/25 | Yes |
| Friesen et al[47] (2004) | Montelukast | FD with duodenal eosinophilia | 40/37 | Yes |
| Bahar et al[48] (2008) | Amitriptyline | Irritable bowel syndrome | 35/33 | Yes |
| Sadeghian et al[49] (2008) | Cyproheptadine | Functional abdominal pain | 36/28 | Yes |
| Saps et al[50] (2009) | Amitriptyline | FD, irritable bowel syndrome, and functional abdominal pain | 90/83 | No |
| Pourmoghaddas et al[51] (2014) | Mebeverine | Functional abdominal pain | 115/87 | No |
- Citation: Friesen CA, Schurman JV, Abdel-Rahman SM. Present state and future challenges in pediatric abdominal pain therapeutics research: Looking beyond the forest. World J Gastrointest Pharmacol Ther 2015; 6(4): 96-104
- URL: https://www.wjgnet.com/2150-5349/full/v6/i4/96.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v6.i4.96
